Identification and characterization of 4-aryl-3,4-dihydropyrimidin-2(1H)-ones as inhibitors of the fatty acid transporter FATP4
Christopher Blackburn(Millennium Engineering and Integration (United States)), Prakash Raman(Millennium Engineering and Integration (United States)), Sandhya Punreddy(Millennium Engineering and Integration (United States)), Suresh K. Balani(Amgen (United States)), Dong Sun(Millennium Engineering and Integration (United States)), Ying Sun(Hohai University), Bing Guan(Toshima Manufacturing (Japan)), Stéphane Peluso(Infinity Pharmaceuticals (United States)), Praveen Sanchetti(Millennium Engineering and Integration (United States)), Virendar K. Kaushik(Broad Institute), Ruth E. Gimeno(Millennium Engineering and Integration (United States)), Peter J. Tummino(Intarcia Therapeutics (United States)), Brian K. Hubbard(Broad Institute), Courtney Cullis(Millennium Engineering and Integration (United States)), Tom Daniels(Millennium Engineering and Integration (United States)), James A. Brown(University of Iowa Health Care), Yingchun Ye(Wuhan University), Tracy J. Jenkins(Millennium Engineering and Integration (United States)), Hui Wu(Fuzhou University), Stephen M. Condon(Millennium Engineering and Integration (United States)), Effie Tozzo(Harvard University)
Cited by 73
Related Papers
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
|The Lancet|2020|3.7k
Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori
|Nature|1999|1.9k
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
|Nature|2012|1.8k
Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase
|Journal of Biological Chemistry|2002|1.4k